A Study of Pasritamig (JNJ-78278343) in Combination With Other Agents for Metastatic Prostate Cancer
Public ClinicalTrials.gov record NCT05818683. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Phase 1b Study of JNJ-78278343, Targeting Human Kallikrein 2 (KLK2) in Combination With Other Agents for Metastatic Prostate Cancer
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
The purpose of this study is to identify the recommended phase 2 regimen(s) RP2R(s) of pasritamig and combination regimens in Part 1 (dose escalation) and to determine safety at the putative RP2R(s) of pasritamig with the combination regimens in Part 2 (dose expansion).
Study identification
- NCT ID
- NCT05818683
- Recruitment status
- Recruiting
- Study type
- Interventional
- Phase
- Phase 1
- Enrollment
- 300 participants
Conditions and interventions
Conditions
Interventions
- Pasritamig Drug
- Cetrelimab Drug
- Cabazitaxel Drug
- Docetaxel Drug
- Apalutamide Drug
- Enzalutamide Drug
- Darolutamide Drug
- Abiraterone acetate plus prednisone (AAP) Drug
- Lutetium Lu-177 vipivotide tetraxetan Drug
- JNJ-101556143 Drug
Drug
Eligibility (public fields only)
- Age range
- 18 Years and older
- Sex
- Male
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Apr 25, 2023
- Primary completion
- Aug 30, 2027
- Completion
- May 22, 2028
- Last update posted
- Aug 27, 2026
2023 – 2028
United States locations
- U.S. sites
- 7
- U.S. states
- 5
- U.S. cities
- 7
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Florida Cancer Specialists | Sarasota | Florida | 34232 | Recruiting |
| Start Midwest | Grand Rapids | Michigan | 49546 | Recruiting |
| Washington University School Of Medicine | St Louis | Missouri | 63110 | Recruiting |
| Perlmutter Cancer Center at NYU Langone Brooklyn | Brooklyn | New York | 11223 | Recruiting |
| Laura & Isaac Perlmutter Cancer Center at NYU Langone Hospital - Long Island | Mineola | New York | 11501 | Recruiting |
| NYU Langone Health | New York | New York | 10016 | Recruiting |
| Sidney Kimmel Cancer Center - Jefferson Health | Philadelphia | Pennsylvania | 19107 | Recruiting |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
Non-U.S. locations
This page focuses on the U.S. directory. The official record also lists 8 non-U.S. sites.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT05818683, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Aug 27, 2026 · Synced Sep 2, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete protocol, eligibility criteria, and contact information for NCT05818683 live on ClinicalTrials.gov.